Opportunity Information: Apply for RFA HL 16 010
Apply for RFA HL 16 010
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Sickle Cell Disease Implementation Consortium (SCDIC) Using Implementation Science to Optimize Care of Adolescents and Adults with Sickle Cell Disease (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.839 Blood Diseases and Resources Research.
- This funding opportunity was created on Jul 15, 2015 and posted on Jul 15, 2015.
- Applicants must submit their applications by Nov 12, 2015. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $4,851,000.00 to eligible and selected applicants.
- Eligible applicants include: Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Special district governments State governments Others (see text field entitled Additional Information on Eligibility for clarification) County governments City or township governments Native American tribal governments (Federally recognized) Independent school districts Private institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The National Institutes of Health (NIH) released this Funding Opportunity Announcement (FOA), RFA-HL-16-010, to build out the Sickle Cell Disease Implementation Consortium (SCDIC) by funding Clinical Sites through a U01 cooperative agreement mechanism. The central purpose is to improve the health and well-being of adolescents and adults living with sickle cell disease (SCD) in the United States by using implementation science to close real-world gaps in care. Rather than focusing on discovering new basic science findings, the emphasis is on putting proven or promising care strategies into practice more reliably and at scale, with a specific target outcome: increasing the rate at which people with SCD receive routine primary care.
A key feature of the opportunity is the expectation that applicants design and carry out multi-modal, multi-sector interventions. In practical terms, that means programs should not rely on a single tactic or one setting alone. Strong applications would typically blend several approaches (for example, clinic workflow changes, care coordination, patient navigation, decision support tools, referral and follow-up systems, patient education, transportation or access supports, and partnerships that address social or administrative barriers). The "multi-sector" element signals that the work should extend beyond a specialty hematology clinic and deliberately connect different parts of the healthcare and community ecosystem, such as primary care practices, hospitals and emergency departments, community organizations, public health entities, insurers, and other local resources that influence whether patients can actually obtain consistent preventive and routine care. The overall goal is to make routine primary care a normal, accessible, and trackable part of life for adolescents and adults with SCD, a population that often experiences fragmented care and heavy reliance on episodic acute services.
Because this is a cooperative agreement (U01), NIH is not simply providing funds and stepping back. A U01 typically means substantial NIH scientific and programmatic involvement during the project period, including coordination across the consortium, shared priorities, common metrics, and collaborative planning. In a consortium model like SCDIC, Clinical Sites are generally expected to contribute to collective learning, harmonize certain data elements or evaluation methods, participate in cross-site meetings or working groups, and help generate results that can be compared across settings and disseminated broadly. The FOA language highlights implementation science, which implies applicants should take a structured approach to identifying barriers and facilitators, selecting strategies matched to those barriers, measuring implementation outcomes (such as reach, adoption, fidelity, acceptability, feasibility, and sustainability), and linking those to clinical and service outcomes like improved primary care utilization.
The announcement strongly encourages multi-disciplinary teams spanning community and academic healthcare institutions. This preference reflects the reality that improving routine primary care use among adolescents and adults with SCD requires coordinated expertise. Competitive teams would typically include clinicians across hematology and primary care, implementation scientists, health services researchers, behavioral health or social work professionals, care coordinators or patient navigators, data and evaluation specialists, and meaningful patient/community representation. The focus on both community and academic partners suggests NIH wanted interventions that are scientifically grounded but also practical and culturally responsive, with strong local partnerships that make adoption and sustainability more likely.
From an administrative standpoint, the FOA is categorized as discretionary funding and falls under the NIH Health activity area, with CFDA 93.839 (Blood Diseases and Resources Research). The posted and creation date was July 15, 2015, and the application closing date was November 12, 2015 (with an archive date of December 13, 2015). NIH listed an estimated total funding amount of $4,851,000 for the opportunity, indicating a moderate-sized, multi-site effort intended to support several Clinical Site awards as part of a larger coordinated initiative.
Eligibility was broad and included many organization types: public and private institutions of higher education, nonprofits (including 501(c)(3) and non-501(c)(3) entities), for-profit organizations (including small businesses and other for-profits), and various government entities (state, county, city/township, special district governments), as well as public housing authorities/Indian housing authorities. The FOA also named several special categories as eligible, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian-serving institutions, and Asian American Native American Pacific Islander-serving institutions, along with faith-based and community-based organizations and eligible federal agencies. At the same time, it clearly excluded non-domestic (non-U.S.) entities and non-domestic components of U.S. organizations, and it did not allow foreign components as defined by NIH policy, reinforcing that this consortium was intended to address U.S.-based SCD care delivery and systems.
The overall takeaway is that this FOA funded applied, collaborative, implementation-focused work at Clinical Sites to raise routine primary care engagement among adolescents and adults with SCD. It prioritized interventions that are comprehensive (multi-modal), cross-cutting (multi-sector), and delivered by teams that can bridge research rigor with on-the-ground healthcare realities in both community and academic settings. For applicants, the core challenge was to propose an intervention package that could be implemented in real clinical environments, evaluated using implementation science methods, and contribute to a shared consortium mission to improve how reliably people with SCD receive routine primary care in the U.S.
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This is a National Institutes of Health (NIH) Funding Opportunity Announcement (FOA) titled RFA-HL-16-010. It supports the expansion of the Sickle Cell Disease Implementation Consortium (SCDIC) by funding Clinical Sites through a U01 cooperative agreement.
What is the main purpose of RFA-HL-16-010?
The central purpose is to improve the health and well-being of adolescents and adults living with sickle cell disease (SCD) in the United States by using implementation science to close real-world gaps in care. The specific target outcome emphasized is increasing the rate at which people with SCD receive routine primary care.
Is this FOA focused on basic science or clinical discovery?
No. The emphasis is not on discovering new basic science findings. It is focused on putting proven or promising care strategies into practice more reliably and at scale in real-world settings.
What is the specific patient population targeted by this opportunity?
The FOA focuses on adolescents and adults living with sickle cell disease (SCD) in the United States, particularly those who experience fragmented care and heavy reliance on episodic acute services.
What is the primary outcome this consortium is aiming to improve?
The FOA highlights a specific target outcome: increasing routine primary care utilization for adolescents and adults with SCD, making primary care a normal, accessible, and trackable part of life.
What does "implementation science" mean in the context of this FOA?
In this FOA, implementation science implies a structured approach to identifying barriers and facilitators to care, selecting implementation strategies that match those barriers, measuring implementation outcomes (such as reach, adoption, fidelity, acceptability, feasibility, and sustainability), and linking those measures to clinical and service outcomes such as improved primary care utilization.
What is meant by "multi-modal" interventions?
"Multi-modal" means the proposed program should not rely on a single tactic. Strong applications are expected to blend multiple approaches, such as clinic workflow changes, care coordination, patient navigation, decision support tools, referral and follow-up systems, patient education, and transportation or access supports.
What is meant by "multi-sector" interventions?
"Multi-sector" means the work should extend beyond a specialty hematology clinic and intentionally connect multiple parts of the healthcare and community ecosystem that influence whether patients obtain consistent routine and preventive care. Examples referenced include primary care practices, hospitals and emergency departments, community organizations, public health entities, insurers, and other local resources.
Does the FOA expect projects to focus only within a hematology clinic?
No. The FOA signals that effective work should deliberately connect beyond specialty hematology and link with broader systems (such as primary care, hospitals/EDs, and community resources) to reduce fragmentation and improve routine primary care engagement.
What types of strategies might be included in a competitive intervention package?
Based on the FOA description, competitive packages would typically combine several elements rather than one. Examples mentioned include clinic workflow changes, care coordination, patient navigation, decision support, referral and follow-up systems, patient education, transportation or access supports, and partnerships that address social or administrative barriers.
What is a U01 cooperative agreement, and why does it matter?
A U01 cooperative agreement indicates substantial NIH scientific and programmatic involvement during the project period. NIH is not simply providing funding and stepping back; the structure usually includes coordination across consortium sites, shared priorities, common metrics, and collaborative planning.
What does participation in a consortium (SCDIC) typically require from Clinical Sites?
The FOA indicates Clinical Sites are generally expected to contribute to collective learning, harmonize certain data elements or evaluation methods, participate in cross-site meetings or working groups, and help generate results that can be compared across settings and disseminated broadly.
Are common metrics or harmonized evaluation approaches expected across sites?
Yes. Because this is a cooperative agreement within a consortium model, the FOA highlights shared priorities and common metrics, along with cross-site coordination and collaborative planning.
What kinds of teams are encouraged to apply?
The FOA strongly encourages multi-disciplinary teams spanning community and academic healthcare institutions. The intent is to combine research rigor with real-world practicality and culturally responsive implementation grounded in strong local partnerships.
What disciplines or roles are typically important for a strong application?
The FOA suggests that improving routine primary care engagement among adolescents and adults with SCD requires coordinated expertise. Examples described include clinicians in hematology and primary care, implementation scientists, health services researchers, behavioral health or social work professionals, care coordinators or patient navigators, data and evaluation specialists, and meaningful patient/community representation.
Is community representation or partnership important in this FOA?
Yes. The FOA emphasizes teams spanning community and academic institutions and calls for meaningful patient/community representation, reflecting a preference for interventions that are practical, locally grounded, and more likely to be adopted and sustained.
What is the NIH activity area and CFDA number for this opportunity?
The FOA is in the NIH Health activity area and is associated with CFDA 93.839 (Blood Diseases and Resources Research).
Is this a discretionary grant program?
Yes. The FOA is categorized as discretionary funding.
When was this FOA posted, and what were the key dates?
The posted/creation date was July 15, 2015. The application closing date was November 12, 2015. The archive date was December 13, 2015.
How much total funding was estimated for this opportunity?
NIH listed an estimated total funding amount of $4,851,000 for the opportunity, intended to support multiple Clinical Site awards as part of a coordinated, multi-site effort.
Who is eligible to apply?
Eligibility is broad and includes public and private institutions of higher education; nonprofits (including 501(c)(3) and non-501(c)(3)); for-profit organizations (including small businesses and other for-profits); and government entities (state, county, city/township, and special district governments), as well as public housing authorities/Indian housing authorities.
Are minority-serving institutions specifically mentioned as eligible?
Yes. The FOA names special categories as eligible, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian-serving institutions, and Asian American Native American Pacific Islander-serving institutions.
Are faith-based and community-based organizations eligible?
Yes. The FOA explicitly includes faith-based and community-based organizations among eligible applicants.
Are federal agencies eligible to apply?
Yes. The FOA lists eligible federal agencies as eligible applicants.
Are non-U.S. (foreign) organizations eligible to apply?
No. The FOA excludes non-domestic (non-U.S.) entities and non-domestic components of U.S. organizations.
Are foreign components allowed within an otherwise eligible U.S. organization?
No. The FOA states it did not allow foreign components as defined by NIH policy, reinforcing that the work is intended to address U.S.-based SCD care delivery and systems.
What is the overall goal of the Sickle Cell Disease Implementation Consortium Clinical Site work?
The overall goal is applied, collaborative, implementation-focused work that improves how reliably adolescents and adults with SCD receive routine primary care in the United States, using comprehensive (multi-modal), cross-cutting (multi-sector) interventions that can be implemented in real clinical environments and evaluated using implementation science methods.
Browse more opportunities from the same category: Health
Next opportunity: Strengthening sustainable public health capacity in the Eastern Mediterranean Region for polio eradication and routine immunization activities
Previous opportunity: Developmental Mechanisms of Human Structural Birth Defects (P01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 16 010
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 16 010) also looked into and applied for these:
| Funding Opportunity |
|---|
| Strengthening sustainable public health capacity in the Eastern Mediterranean Region for polio eradication and routine immunization activities Apply for CDC RFA GH16 1601 Funding Number: CDC RFA GH16 1601 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $40,000,000 |
| Data Coordinating Center for Sickle Cell Disease Implementation Consortium (SCDIC) Using Implementation Science to Optimize Care of Adolescents and Adults with Sickle Cell Disease (U24) Apply for RFA HL 16 011 Funding Number: RFA HL 16 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Tracking Electronic Health Record Adoption And Capturing Related Insights in U.S. Hospitals Apply for NAP AX 15 006 Funding Number: NAP AX 15 006 Agency: Office of the National Coordinator Category: Health Funding Amount: $204,000 |
| GLOBAL DEVELOPMENT ALLIANCE ANNUAL PROGRAM STATEMENT Improving the Health Status of Rwandans. Apply for RFA 696 15 000009 Funding Number: RFA 696 15 000009 Agency: Rwanda USAID Kigali Category: Health Funding Amount: $2,000,000 |
| Measuring Progress Regarding Interoperability through Individuals Access and Use of their Electronic Health Data Apply for NAP AX 15 007 Funding Number: NAP AX 15 007 Agency: Office of the National Coordinator Category: Health Funding Amount: $50,000 |
| Alcohol Use Disorders Behavioral Treatment, Services and Recovery Research (R01) Apply for PA 15 299 Funding Number: PA 15 299 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Planning Grant for Healthcare and Public Health Sector Cybersecurity Information Sharing Apply for EP HIT 15 002 Funding Number: EP HIT 15 002 Agency: Assistant Secretary for Preparedness and Response Category: Health Funding Amount: $150,000 |
| Collaborative Projects to Accelerate Research in Organ Fibrosis (R01) Apply for RFA HL 16 003 Funding Number: RFA HL 16 003 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Alcohol Use Disorders Behavioral Treatment, Services and Recovery Research (R03) Apply for PA 15 300 Funding Number: PA 15 300 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Alcohol Use Disorders Behavioral Treatment, Services and Recovery Research (R21) Apply for PA 15 301 Funding Number: PA 15 301 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Establishing Outcome Measures for Clinical Studies of Oral and Craniofacial Diseases and Conditions (R21) Apply for PAR 15 298 Funding Number: PAR 15 298 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Establishing Outcome Measures for Clinical Studies of Oral and Craniofacial Diseases and Conditions (R01) Apply for PAR 15 302 Funding Number: PAR 15 302 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| PPHF 2015 Immunization Capacity Building Assistance for Infrastructure Enhancements to Meet Interoperability Requirements financed in part by 2015 Prevention and Public Health Funds Apply for CDC RFA IP14 1404PPHF15 Funding Number: CDC RFA IP14 1404PPHF15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Development, Operation and Evaluation of an Entertainment Education Program Technical Assistance Cooperative Agreement Apply for CDC RFA CD12 120105CONT15 Funding Number: CDC RFA CD12 120105CONT15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| PPHF2015 Nutrition, Physical Activity Apply for RFA DP 14 01102PPHF15 Funding Number: RFA DP 14 01102PPHF15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Planning and Management of a Public Health Communication and Community Engagement Technical Assistance Cooperative Agreement Apply for CDC RFA CD11 110105CONT15 Funding Number: CDC RFA CD11 110105CONT15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Clinical and Translational Science Award (U54) Apply for PAR 15 304 Funding Number: PAR 15 304 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Global Measles Elimination Apply for CDC RFA IP11 110505CONT16 Funding Number: CDC RFA IP11 110505CONT16 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Technical Support to PEPFAR Programs in the Southern Africa Region Apply for RFA 674 15 000007 Funding Number: RFA 674 15 000007 Agency: South Africa USAID Pretoria Category: Health Funding Amount: $69,845,000 |
| PPHF 2015 Nutrition, Physical Activity Apply for RFA DP 15 008 Funding Number: RFA DP 15 008 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 16 010", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.